Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 ...

The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...

Roivant Sciences ROIV stock surged on Friday on positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS), an ...

Housing and Local Government Minister Nga Kor Ming has urged all parties to be patient and wait for the study report by the ...

The International Islamic University Malaysia (IIUM) has the capability and credibility to conduct academic studies on the ...

Immunovant, Inc. (NASDAQ:IMVT) Q3 2026 Earnings Call Transcript February 6, 2026 Immunovant, Inc. beats earnings expectations. Reported EPS is $-0.60951, expectations were $-0.72. Operator: Good day, ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 ...

An independent predictor of CS-responsive MG was ptosis (OR, 2.13; 95% CI, 1.05-4.32), but this association only remained when AChR antibody–positive status was an independent predictor of CRMG (OR, 2 ...

Over the past two years, Indian students have faced an unprecedented spike in visa refusals, long processing delays, and confusion over housing and post-study work rules. Following a “reset”, clarity ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (?21.6 PPriova ...

Q3 2025 earnings call: brepocitinib Phase II wins, Phase III plans, 2026 catalysts, $4.5B cash & Moderna trial—read key insights.

Only a few weeks ago, the Stevens population returned for the spring semester. While most came back this semester to continue in their given program, many freshmen— myself included—came back to start ...